Regorafenib Plus PD-1 Inhibitor in Patients With Colorectal Cancer
Status:
Recruiting
Trial end date:
2021-08-31
Target enrollment:
Participant gender:
Summary
This study is intended to evaluate efficacy and safety of the combination of regorafenib and
nivolumab as third-line or later therapy in patients with microsatellite stable (MSS)
colorectal cancer (CRC).